Notably, patients with diabetes with AD-related cognitive impairment using DPP-4 inhibitors exhibit a lesser amyloid burden and slower cognitive decline compared to patients without diabetes or patients with diabetes taking other glucose-lowering medications [82]. The gene discussed is DPP4; the disease is diabetes mellitus.